Caladrius Biosciences to Participate at Upcoming January Conferences
January 07 2020 - 4:05PM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a late-stage therapeutics development biopharmaceutical
company pioneering advancements of cell therapies in select
cardiovascular and autoimmune diseases, announced today that the
Company will present at the following conferences in January:
The 2020 Biotech Showcase
|
Date: |
Tuesday, January 14, 2020 |
| Time: |
10:00 a.m. (PST) |
| Track: |
Yosemite A (Ballroom Level) |
| Location: |
Hilton San Francisco Union Square
in San Francisco, CA |
| Presenter: |
David J. Mazzo, PhD, President
and Chief Executive Officer of Caladrius Biosciences |
World Stem Cell Summit 2020
|
Date: |
Wednesday, January 22, 2020 |
| Time: |
9:45 a.m. – 10:30 a.m. (EST) |
| Panel: |
The ALPHA Clinic |
| Location: |
Hyatt Regency in Miami, FL |
| Presenter: |
Douglas W. Losordo, MD, FACC,
FAHA, Executive Vice President, Global Head of Research and
Development, and Chief Medical Officer of Caladrius
Biosciences |
About Caladrius
BiosciencesCaladrius is a late-stage therapeutics
development biopharmaceutical company pioneering advancements of
cell therapies for select cardiovascular and autoimmune
diseases. Our leadership team collectively has decades of
biopharmaceutical development experience and world-recognized
scientific achievement in the fields of cardiovascular and
autoimmune disease, among other areas. Our current product
candidates include three developmental treatments for
cardiovascular diseases based on our CD34+ cell therapy platform:
CLBS12, recipient of a SAKIGAKE designation in Japan and advanced
therapy medicinal product classification (ATMP) in Europe, eligible
for early conditional approval for the treatment of critical limb
ischemia in Japan based on an ongoing clinical trial; CLBS16,
subject of the proof-of-concept ESCaPE-CMD clinical trial in the
U.S.A. for the treatment of coronary microvascular dysfunction; and
CLBS14, a Phase 3 ready clinical program in no option refractory
disabling angina and recipient of a RMAT designation in the
U.S.A. For more information on the company, please
visit www.caladrius.com
Contact:
Investors: Caladrius Biosciences, Inc. John
Menditto Vice President, Investor Relations and Corporate
Communications Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024
